3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
8
Glioma
4
Multiple Myeloma
3
Thyroid Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Astrocytoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Interventions
fludarabine
25
Cyclophosphamide
20
Azacitidine
20
venetoclax
18
Specimen Handling
18
fludarabine phosphate
17
Mycophenolic Acid
14
Melphalan
14
Busulfan
14
Biopsy
14
Whole-Body Irradiation
13
Tacrolimus
12
Cytarabine
12
Granulocyte Colony-Stimulating Factor
10
decitabine and cedazuridine drug combination
9
Decitabine
9
Stem Cell Transplantation
8
Sirolimus
8
Injections
8
Filgrastim
8
Cyclosporine
8
Peripheral Blood Stem Cell Transplantation
7
Thiotepa
6
ruxolitinib
5
X-Rays
5
Idarubicin
5
Magnetic Resonance Spectroscopy
4
Cladribine
4
CPX-351
4
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
dabrafenib
×
90 days
×
Clear all
No trials found.